1,25-dihydroxyvitamin D3 and dexamethasone increase interleukin-10 production in CD4+ T cells from patients with Crohn's disease

Background and aimIn Crohn's disease (CD), epidemiological data and animal studies suggest that vitamin D (vitD) has protective immune-modulating properties. 1,25-dihydroxyvitamin D3 and dexamethasone (DEX) induce interleukin (IL)-10 productions in healthy controls (HC) T cells. We studied if 1,25-dihydroxyvitamin D3 with and without DEX could induce IL-10 production, downregulate pro-inflammatory Interferon (IFN)-γ and Tumor Necrosis Factor (TNF)-α production, and influence cell kinetics in peripheral CD4+ T cells from CD patients.MethodsCD4+ T cells were separated from peripheral blood from CD patients and HC. Cells were activated by anti-CD3 and anti-CD28 in the presence of 1,25-dihydroxyvitamin D3 and/or DEX. Cytokine levels, proliferation, and apoptosis were measured following 7 days of culture.ResultsIn T cells from CD patients, 1,25-dihydroxyvitamin D3 and DEX increased IL-10 production from a median of 0.08 ng/ml to 0.2 ng/ml (p < 0.01) and downregulated IFN-γ production from 8.3 ng/ml to 3.1 ng/ml (p < 0.01). The induced IL-10 increase in cultures from HC (0.2 ng/ml to 1.0 ng/ml, p < 0.01) was significantly higher than in CD patients (p < 0.05). In CD cultures, the IL-4 production increased from 0.3 ng/ml to 0.5 ng/ml (p < 0.01) and IL-6 production from 2.5 ng/ml to 6.1 ng/ml (p < 0.05). Similar changes in cytokine levels were observed with 1,25-dihydroxyvitamin D3 independently of DEX. In addition, 1,25-dihydroxyvitamin D3 and DEX decreased proliferation and reduced viability of T cells.ConclusionWe found that 1,25-dihydroxyvitamin D3 with and without DEX stimulation increased IL-10 and reduced IFN-γ production. These findings suggest that vitD may play a therapeutic role in CD.